The proposed studies aim to define the cognitive impairment associated with SPD and to evaluate the effect of an acute pharmacologic intervention with amphetamine on the cognitive function of SPD patients. SPD patients share important phenomenologic, genetic, and neurobiologic commonalities with chronic schizophrenia, particularly a core cognitive/attentional impairment. Their study, however, minimized the multiple confounding artifacts associated with the study of schizophrenic patients and offers an opportunity to potentially disentangle the multiple pathophysiologic mechanisms implicated in the schizophrenic disorders. Like schizophrenic patients, SPD patients demonstrate impaired performance on tests of visuospatial working memory, verbal learning, and sustained attention compared to other personality disorder patients and normal controls in the investigator's studies to date. Preliminary data suggests amphetamine can ameliorate these cognitive impairments in SPD patients. This study is designed to test the primary hypotheses that SPD patients will show cognitive impairment in both verbal and visuospatial domains respectively in three areas of cognitive function compared to other non-odd cluster personality disorder (OPD) patients and normal controls: 1) working memory (Paced Auditory Serial Addition Test (PASAT) and DOT tests) 2) learning and memory (serial word list learning and Wechsler Memory Scale Visual Reproduction (WMS-VR)) and 3) sustained attention (Continuous Performance Task (CPT-IP), digits and shapes. SPD patients will be evaluated on these cognitive tasks during placebo and amphetamine to test the hypothesis that 4) they will demonstrate significant improvement in performance in these three domains after administration of 30 mgs. of oral amphetamine and 5) there will be a significant diagnosis by drug interaction for the performance of these cognitive tasks with the SPD group demonstrating significantly improved performance compared to the OPD or the normal comparison group after amphetamine compared to placebo.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH056140-04
Application #
6186540
Study Section
Clinical Neuroscience and Biological Psychopathology Review Committee (CNBP)
Project Start
1997-04-01
Project End
2002-03-31
Budget Start
2000-04-14
Budget End
2001-03-31
Support Year
4
Fiscal Year
2000
Total Cost
$243,981
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Psychiatry
Type
Schools of Medicine
DUNS #
114400633
City
New York
State
NY
Country
United States
Zip Code
10029
Hazlett, Erin A; Rothstein, Ethan G; Ferreira, Rui et al. (2015) Sensory gating disturbances in the spectrum: similarities and differences in schizotypal personality disorder and schizophrenia. Schizophr Res 161:283-90
Rosell, Daniel R; Futterman, Shira E; McMaster, Antonia et al. (2014) Schizotypal personality disorder: a current review. Curr Psychiatry Rep 16:452
Thompson, Judy L; Rosell, Daniel R; Slifstein, Mark et al. (2014) Prefrontal dopamine D1 receptors and working memory in schizotypal personality disorder: a PET study with [¹¹C]NNC112. Psychopharmacology (Berl) 231:4231-40
McClure, Margaret M; Harvey, Philip D; Bowie, Christopher R et al. (2013) Functional outcomes, functional capacity, and cognitive impairment in schizotypal personality disorder. Schizophr Res 144:146-50
Roussos, Panos; Bitsios, Panos; Giakoumaki, Stella G et al. (2013) CACNA1C as a risk factor for schizotypal personality disorder and schizotypy in healthy individuals. Psychiatry Res 206:122-3
Harvey, Philip D; McClure, Margaret M; Patterson, Thomas L et al. (2012) Impairment in functional capacity as an endophenotype candidate in severe mental illness. Schizophr Bull 38:1318-26
Kent, Brendon W; Weinstein, Zachary A; Passarelli, Vincent et al. (2011) Deficient visual sensitivity in schizotypal personality disorder. Schizophr Res 127:144-50
Perez-Rodriguez, M Mercedes; Weinstein, Shauna; New, Antonia S et al. (2010) Tryptophan-hydroxylase 2 haplotype association with borderline personality disorder and aggression in a sample of patients with personality disorders and healthy controls. J Psychiatr Res 44:1075-81
Stanley, Barbara; Siever, Larry J (2010) The interpersonal dimension of borderline personality disorder: toward a neuropeptide model. Am J Psychiatry 167:24-39
Siever, Larry J; Weinstein, Lissa N (2009) The neurobiology of personality disorders: implications for psychoanalysis. J Am Psychoanal Assoc 57:361-98

Showing the most recent 10 out of 26 publications